Article ID Journal Published Year Pages File Type
8679309 Thrombosis Research 2018 20 Pages PDF
Abstract
In conclusion, dabigatran etexilate may provide a viable and more convenient alternative to LMWH in the long-term treatment of VM-LIC. The dose has to be tailored in each patient in function of the bleeding tendency and laboratory hemostasis parameters.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Preview
Dabigatran etexilate in the treatment of localized intravascular coagulopathy associated with venous malformations
Authors
, , ,